Cargando…
Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
INTRODUCTION: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a condition that is characterized by urgency, frequency and/or pelvic pain. The disease occurs mainly in women. BPS/IC can be severe enough to have a significant impact on patients' quality of life, but it can also be associa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Polish Urological Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318027/ https://www.ncbi.nlm.nih.gov/pubmed/34336239 http://dx.doi.org/10.5173/ceju.2021.0340.R1 |
_version_ | 1783730170500218880 |
---|---|
author | Kasyan, George Kupriyanov, Yury Karasev, Alexander Baibarin, Kirill Pushkar, Dmitry |
author_facet | Kasyan, George Kupriyanov, Yury Karasev, Alexander Baibarin, Kirill Pushkar, Dmitry |
author_sort | Kasyan, George |
collection | PubMed |
description | INTRODUCTION: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a condition that is characterized by urgency, frequency and/or pelvic pain. The disease occurs mainly in women. BPS/IC can be severe enough to have a significant impact on patients' quality of life, but it can also be associated with moderate symptoms that are equally debilitating. The aim of this article was to evaluate the possibility of the use of pentosan polysulfate sodium in patients in the complex treatment of BPS/IC. MATERIAL AND METHODS: A multicenter, double-blind, placebo-controlled, randomized study was conducted in parallel groups in 7 Russian medical centers. RESULTS: Efficacy and safety have been established as the main criteria. A total of 93 patients were screened. Statistical analysis was performed. It has been shown that pentosan therapy is more effective than in the placebo. Average change in the number of points on the scale O'Leary-Santa Interstitial Cystitis Symptom Index compared to baseline data in the pentosan group 4.93 ±3, 03, in the placebo group 1.66 ±3.19 (p = 0.014), and the adverse events and safety of pentosan are comparable to the placebo group. CONCLUSIONS: Oral glycosaminoglycan (pentosan polusulfate sodium) is an effective and safe drug and should be included in the complex treatment of patients with bladder pain syndrome/interstitial cystitis. |
format | Online Article Text |
id | pubmed-8318027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Polish Urological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-83180272021-07-30 Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study Kasyan, George Kupriyanov, Yury Karasev, Alexander Baibarin, Kirill Pushkar, Dmitry Cent European J Urol Original Paper INTRODUCTION: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a condition that is characterized by urgency, frequency and/or pelvic pain. The disease occurs mainly in women. BPS/IC can be severe enough to have a significant impact on patients' quality of life, but it can also be associated with moderate symptoms that are equally debilitating. The aim of this article was to evaluate the possibility of the use of pentosan polysulfate sodium in patients in the complex treatment of BPS/IC. MATERIAL AND METHODS: A multicenter, double-blind, placebo-controlled, randomized study was conducted in parallel groups in 7 Russian medical centers. RESULTS: Efficacy and safety have been established as the main criteria. A total of 93 patients were screened. Statistical analysis was performed. It has been shown that pentosan therapy is more effective than in the placebo. Average change in the number of points on the scale O'Leary-Santa Interstitial Cystitis Symptom Index compared to baseline data in the pentosan group 4.93 ±3, 03, in the placebo group 1.66 ±3.19 (p = 0.014), and the adverse events and safety of pentosan are comparable to the placebo group. CONCLUSIONS: Oral glycosaminoglycan (pentosan polusulfate sodium) is an effective and safe drug and should be included in the complex treatment of patients with bladder pain syndrome/interstitial cystitis. Polish Urological Association 2021-05-07 2021 /pmc/articles/PMC8318027/ /pubmed/34336239 http://dx.doi.org/10.5173/ceju.2021.0340.R1 Text en Copyright by Polish Urological Association https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Kasyan, George Kupriyanov, Yury Karasev, Alexander Baibarin, Kirill Pushkar, Dmitry Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study |
title | Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study |
title_full | Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study |
title_fullStr | Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study |
title_full_unstemmed | Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study |
title_short | Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study |
title_sort | safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318027/ https://www.ncbi.nlm.nih.gov/pubmed/34336239 http://dx.doi.org/10.5173/ceju.2021.0340.R1 |
work_keys_str_mv | AT kasyangeorge safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy AT kupriyanovyury safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy AT karasevalexander safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy AT baibarinkirill safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy AT pushkardmitry safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy |